Studying Families with Systemic Scleroderma to Understand the Disease
Studies family members with systemic scleroderma to find markers of disease progression.
Plain-language title generated from the registry record
Registry title: Familial Systemic Scleroderma
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - FranceStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07343115
- Record updated
- 15 January 2026
- Original description
Studying familial forms of systemic scleroderma offers several advantages:Read full original descriptionShow less
Familial Systemic Scleroderma
Studying familial forms of systemic scleroderma offers several advantages:
1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Inclusion: Adult subjects (≥ 18 years of age); Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities; At least one first-degree relative with systemic scleroderma meeting the same criteria.
Exclusion: Subject who has expressed opposition to participating in the study.